drugset / Trial / NCT01926639
Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma
Phase 2
Completed
14 enrolled
Oslo University Hospital
Helse Sor-Ost · collabNorwegian Cancer Society · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients with non-curable disseminated follicular lymphoma receive local radiotherapy targeting single lymph nodes and injection of low-dose rituximab (anti-CD20) and autologous dendritic cells. The therapy is repeated 3 times, targeting different lesion. Aims are to induce tumor immunity and clinical responses.
Timeline
- Start
- 2009-10
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 5 mg | Other |
| Subject | Rituximab | Monoclonal antibody | — | Other |